Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 3:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 489 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vision Center Clear all
Completed No phase listed Observational Accepts healthy volunteers

Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration

NCT01174771
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Corticobasal Degeneration, Parkinsonism
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
35 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Jun 10, 2026, 3:37 AM EDT
Withdrawn Not applicable Interventional

A Clinical Study Comparing the Comfort of Three Commercially Available Contact Lenses

NCT02298400
View directory record Official record
Conditions
Contact Lens Complication
Interventions
Acuvue® Oasys® Lenses (senofilcon A), 30-Day Bausch + Lomb PureVision (balafilcon A), Clariti® 1-Day (Somofilcon A)
Device
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Jun 10, 2026, 3:37 AM EDT
Completed Phase 3 Interventional Results available

Increasing Patching for Amblyopia in Children 3 to < 8 Years Old

NCT00945100
View directory record Official record
Conditions
Amblyopia
Interventions
Eye Patch
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 7 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Fullerton, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Jun 10, 2026, 3:37 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A 6 Month Study to Evaluate the Safety, Analgesic Efficacy of ACUVAIL™ (Ketorolac Tromethamine Ophthalmic Solution) 0.45%, in Post-PRK Corneal Wound Healing

NCT01193231
View directory record Official record
Conditions
Must be PRK Candidate
Interventions
Not listed
Lead sponsor
Durrie Vision
Other
Eligibility
18 Years to 39 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Jun 10, 2026, 3:37 AM EDT
Completed Phase 1 Interventional

Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104

NCT03413319
View directory record Official record
Conditions
Progressive Supranuclear Palsy (PSP)
Interventions
ABBV-8E12
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
La Jolla, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Jun 10, 2026, 3:37 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Factors in Learning And Plasticity: Healthy Vision

NCT05439759
View directory record Official record
Conditions
Central Visual Impairment, Macular Degeneration
Interventions
Condition 1: Training visual sensitivity, Condition 2: Training spatial integration, Condition 3: Training spatial attention, Condition 4: Combination training
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 30 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Birmingham, Alabama • Riverside, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jun 10, 2026, 3:37 AM EDT
Completed No phase listed Observational

Prospective Evaluation of a Smartphone Application, GoCheckKids™, to Detect Amblyopia Risk Factors in Young Children

NCT03447171
View directory record Official record
Conditions
Amblyopia
Interventions
App Vision Screening
Device
Lead sponsor
Gobiquity Mobile Health
Industry
Eligibility
1 Year to 8 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Jun 10, 2026, 3:37 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness

NCT01959230
View directory record Official record
Conditions
Hyperemia
Interventions
Brimonidine Tartrate, Vehicle, Sodium Fluorescein, Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Jun 10, 2026, 3:37 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

NCT02365922
View directory record Official record
Conditions
FTLD, Progressive Supranuclear Palsy (PSP), Frontotemporal Dementia (FTD), Corticobasal Degeneration (CBD), PPA Syndrome, Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis (ALS), Oligosymptomatic PSP (oPSP), Corticobasal Syndrome (CBS)
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 85 Years
Enrollment
1,489 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Jun 10, 2026, 3:37 AM EDT
Completed Not applicable Interventional Results available

Multisensory Rehabilitation of Hemianopia

NCT04963075
View directory record Official record
Conditions
Hemianopia
Interventions
multisensory rehabilitation paradigm
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jun 10, 2026, 3:37 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers

NCT00223951
View directory record Official record
Conditions
Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis
Interventions
R89674 (generic name not yet established)
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
3 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
6
States / cities
Phoenix, Arizona • Bel Air, Maryland • North Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2015 · Synced Jun 10, 2026, 3:37 AM EDT
Not listed Phase 4 Interventional

Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma

NCT04981886
View directory record Official record
Conditions
Normal Tension Glaucoma
Interventions
Netarsudil Ophthalmic, Bimatoprost Ophthalmic
Drug
Lead sponsor
Salus University
Other
Eligibility
21 Years to 89 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Vestal, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Jun 10, 2026, 3:37 AM EDT
Completed No phase listed Observational

A Study of Detection of Paroxysmal Events Utilizing Computer Vision and Machine Learning

NCT04738552
View directory record Official record
Conditions
Epilepsy
Interventions
Nelli
Device
Lead sponsor
Neuro Event Labs Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Jun 10, 2026, 3:37 AM EDT
Recruiting Not applicable Interventional

Patch-free Occlusion Therapy

NCT05440448
View directory record Official record
Conditions
Amblyopia
Interventions
Patch-free occlusion therapy, Adhesive patch
Device
Lead sponsor
Retina Foundation of the Southwest
Other
Eligibility
3 Years to 12 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jun 10, 2026, 3:37 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluate the TetraLens, a Tetracaine Releasing Therapeutic Bandage Contact Lens in Patients Undergoing PRK Procedure

NCT06085352
View directory record Official record
Conditions
Ocular Pain
Interventions
TetraLens bandage contact lens, Control Acuvue Oasys Bandage contact Lens
Drug · Device
Lead sponsor
Vance Thompson Vision
Other
Eligibility
22 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Jun 10, 2026, 3:37 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Jun 10, 2026, 3:37 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Astronaut Vision Issues in a Ground Analog Population: Polycystic Ovary Syndrome

NCT02896452
View directory record Official record
Conditions
Polycystic Ovarian Syndrome, Idiopathic Intracranial Hypertension
Interventions
Not listed
Lead sponsor
National Aeronautics and Space Administration
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jun 10, 2026, 3:37 AM EDT
Terminated Not applicable Interventional Results available

Spectacle Tints and Thin-Films for Migraine

NCT02720211
View directory record Official record
Conditions
Headache Migraine Chronic
Interventions
Gray tinted spectacle lenses, Thin-Film spectacle lenses
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Phoenix, Arizona • Boston, Massachusetts • Great Neck, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Jun 10, 2026, 3:37 AM EDT
Completed Phase 3 Interventional Results available

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

NCT02558374
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID, Placebo
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Jun 10, 2026, 3:37 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

NCT07482176
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions
Ixo-vec, Aflibercept
Genetic · Drug
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
46
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 10, 2026, 3:37 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Carotenoids for Collision Athletes

NCT06270680
View directory record Official record
Conditions
Head Injury, Carotenoids
Interventions
Vision Edge Pro, Placebo
Drug · Other
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Jun 10, 2026, 3:37 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Light-deprivation Utilized to Mitigate Amblyopia

NCT02685423
View directory record Official record
Conditions
Amblyopia
Interventions
Binocular deprivation 10 days, Vision training
Behavioral
Lead sponsor
State University of New York College of Optometry
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Jun 10, 2026, 3:37 AM EDT
Active, not recruiting No phase listed Observational

Remote Monitoring in Progressive Supranuclear Palsy (PSP)

NCT04753320
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Parkinson Disease, MSA - Multiple System Atrophy
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 89 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Jun 10, 2026, 3:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers

NCT02392468
View directory record Official record
Conditions
Schizophrenia, Alzheimer Disease
Interventions
Placebo matching BI 409306 25 mg, Placebo matching BI 409306 50 mg, BI 409306 25 mg, BI 409306 50 mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
La Jolla, California • Eatontown, New Jersey • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Jun 10, 2026, 3:37 AM EDT